Information

Related Research Units

Nephrology Research

Publications

  1. Discovery of Conformationally Constrained ALK2 Inhibitors. J Med Chem. 2024 03 28; 67(6):4707-4725. View Abstract
  2. Limbal BCAM expression identifies a proliferative progenitor population capable of holoclone formation and corneal differentiation. Cell Rep. 2022 08 09; 40(6):111166. View Abstract
  3. Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. Gastroenterology. 2021 05; 160(6):1947-1960. View Abstract
  4. Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. J Med Chem. 2020 09 10; 63(17):10061-10085. View Abstract
  5. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism. J Biol Chem. 2020 05 29; 295(22):7774-7788. View Abstract
  6. ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer. J Biol Chem. 2018 07 13; 293(28):11166-11178. View Abstract
  7. Expression of Cell-Surface Marker ABCB5 Causes Characteristic Modifications of Glucose, Amino Acid and Phospholipid Metabolism in the G3361 Melanoma-Initiating Cell Line. PLoS One. 2016; 11(8):e0161803. View Abstract
  8. ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth. J Invest Dermatol. 2016 Apr; 136(4):838-846. View Abstract
  9. An argument for early genomic sequencing in atypical cases: a WISP3 variant leads to diagnosis of progressive pseudorheumatoid arthropathy of childhood. Rheumatology (Oxford). 2016 Mar; 55(3):586-9. View Abstract
  10. ABCB5 is a limbal stem cell gene required for corneal development and repair. Nature. 2014 Jul 17; 511(7509):353-7. View Abstract
  11. ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res. 2014 Aug 01; 74(15):4196-207. View Abstract
  12. Stem cells and targeted approaches to melanoma cure. Mol Aspects Med. 2014 Oct; 39:33-49. View Abstract
  13. Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk. Biochem Biophys Res Commun. 2013 Jul 05; 436(3):536-42. View Abstract
  14. Genomic convergence among ERRa, PROX1, and BMAL1 in the control of metabolic clock outputs. PLoS Genet. 2011 Jun; 7(6):e1002143. View Abstract
  15. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 2011 Aug 01; 71(15):5307-16. View Abstract
  16. Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. Curr Colorectal Cancer Rep. 2011 Jun; 7(2):128-135. View Abstract
  17. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res. 2011 Feb 15; 71(4):1474-85. View Abstract
  18. Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun. 2010 Nov 26; 402(4):711-7. View Abstract
  19. An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha. Mol Endocrinol. 2010 Jul; 24(7):1349-58. View Abstract
  20. The homeobox protein Prox1 is a negative modulator of ERR{alpha}/PGC-1{alpha} bioenergetic functions. Genes Dev. 2010 Mar 15; 24(6):537-42. View Abstract
  21. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene. 2009 Jul 23; 28(29):2634-42. View Abstract
  22. CUX1 transcription factor is a downstream effector of the proteinase-activated receptor 2 (PAR2). J Biol Chem. 2009 Jan 02; 284(1):36-45. View Abstract
  23. Meta-analysis of SUMO1. BMC Res Notes. 2008 Jul 31; 1:60. View Abstract
  24. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer. 2008 Jun 04; 7:49. View Abstract
  25. Does GATA3 act in tissue-specific pathways? A meta-analysis-based approach. J Carcinog. 2008; 7:6. View Abstract
  26. Phosphorylation-dependent sumoylation regulates estrogen-related receptor-alpha and -gamma transcriptional activity through a synergy control motif. Mol Endocrinol. 2008 Mar; 22(3):570-84. View Abstract
  27. Identification of novel pathway partners of p68 and p72 RNA helicases through Oncomine meta-analysis. BMC Genomics. 2007 Nov 15; 8:419. View Abstract
  28. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab. 2007 May; 5(5):345-56. View Abstract
  29. The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase. Mol Cell Biol. 2006 Mar; 26(6):2441-55. View Abstract
  30. The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J. 2005 Feb 09; 24(3):543-53. View Abstract
  31. The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner. BMC Mol Biol. 2004 Aug 06; 5:11. View Abstract
  32. The highly related DEAD box RNA helicases p68 and p72 exist as heterodimers in cells. Nucleic Acids Res. 2003 Mar 01; 31(5):1470-80. View Abstract
  33. A novel form of the RelA nuclear factor kappaB subunit is induced by and forms a complex with the proto-oncogene c-Myc. Biochem J. 2002 Sep 01; 366(Pt 2):459-69. View Abstract

Contact Brian Wilson

Phone: 617-919-2980
Print Profile